AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02595827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conditional Advice
Description: Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
Study NCT04572672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting
Description: Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study.
Study NCT03150563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretch
Description: Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
Study NCT02678052 — intervention group
Intervention type: DRUG
Intervention: Vedolizumab
Description: Vedolizumab exposure
Study NCT02678052 — intervention group
Intervention type: BIOLOGICAL
Intervention: Other Biological Agent
Description: Other Biological Agent exposure
Study NCT02521844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1922159
Description: Oral administration
Study NCT02521844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration
Study NCT04102449 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Single arm receiving Apremilast and ultrasound examinations
Study NCT03055767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OnabotulinumtoxinA
Description: The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
Study NCT00682916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Y288
Description: Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
Study NCT01784016 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-PHNO
Description: \[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
Study NCT02666417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge (MNP+iron)
Description: Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
Study NCT02666417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge (MNP+iron+GOS)
Description: Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
Study NCT00277043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, docetaxel, taxane
Description: 1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
Study NCT00277043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxane
Description: The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
Study NCT02719704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEXA-SE
Description: MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher.
Study NCT02719704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Espelho, espelho meu
Description: Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters.
Study NCT03055767 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (Saline)
Description: The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
Study NCT02759731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
Study NCT03883438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified coronally advanced flap and acellular dermal matrix graft
Description: Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
Study NCT03883438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced flap and acellular dermal matrix graft
Description: Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
Study NCT00906620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPR: question, persuade and refer (SEYLE)
Description: The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies.
Study NCT01680094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
Study NCT00760227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
Study NCT00760227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Humor Therapy
Description: For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
Study NCT00760227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Therapy
Description: In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
Study NCT03257930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol injection
Description: inject ethanol in cystic thyroid nodule and follow up until complete recovery
Study NCT01013909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifonazole spray once daily
Description: Application of one dose daily by means of an metered dose
Study NCT01013909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifonazole spray twice daily
Description: Application of two dose daily by means of an metered dose
Study NCT01013909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of one dose daily by means of an metered dose
Study NCT02438696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, iFF, Test
Study NCT02438696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF1, Reference
Study NCT02438696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469, TF2, Test
Study NCT02680717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene
Description: ointment, twice daily
Study NCT02680717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: ointment, 0.1%, twice daily
Study NCT02254941 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Metastatic colon cancer, first line treatment with conventional chemotherapy
Study NCT02254941 — intervention group
Intervention type: BIOLOGICAL
Intervention: Chemotherapy plus monoclonal antibody
Description: Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
Study NCT03760055 — intervention group
Intervention type: DEVICE
Intervention: nGoggle
Description: The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
Study NCT00302185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
Study NCT00302185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led supportive care
Description: 20-30 minutes of supportive attention from an experienced palliative nurse.
Study NCT01013909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil Once
Description: One application of Lamisil Once
Study NCT03660813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follicle measurment
Description: Follicle will be measured before aspiration
Study NCT03660813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle ( Hcg 250 mcg)
Description: Drug used for triggering
Study NCT03660813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl ( GnRH Agonist 0.1 mg*2 )
Description: Drug used for triggering
Study NCT02547831 — intervention group
Intervention type: OTHER
Intervention: Observational approach
Description: Patients will be placed under wait and see approach without any specific treatment
Study NCT03026543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Recruitment Maneuver
Study NCT03026543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Study NCT03026543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Study NCT03026543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator
Study NCT03026543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator
Study NCT01614769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
Study NCT00472953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study NCT00472953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, pre-prandial, injection s.c.
Study NCT03110796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dressing with LU3103209 - Dose 1
Description: Dressing with LU3103209 - Dose 1
Study NCT03110796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dressing with LU3103209 - Dose 2
Description: Dressing with LU3103209 - Dose 2
Study NCT03110796 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing without LU3103209
Description: Dressing without LU3103209
Study NCT03355196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRX712
Description: Ascending single dose on Day 1
Study NCT03355196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single dose on Day 1
Study NCT01813435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
Study NCT01813435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
Study NCT01813435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
Study NCT01813435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
Study NCT01813435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy
Study NCT02419625 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: questionnaires
Description: questionnaires , serum samples will be used
Study NCT02598245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOT 8/4
Description: placement of transobturator sling according to the TOT 8/4 technique
Study NCT02598245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOT 6/3
Description: placement of transobturator sling according to the TOT 6/3 technique
Study NCT03300908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ADHERE
Description: This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals.
Study NCT03300908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MACE
Description: This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
Study NCT05193773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial interventions
Description: The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
Study NCT02333188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02333188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02333188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02333188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02333188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02546050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03299465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
Study NCT01816074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamphetamine)
Description: Active ADHD drug, Vyvanse, is administered to mother.
Study NCT01816074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Parent Training
Description: Mother is given 8 weeks of individual sessions of behavioral parent training
Study NCT02938429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days
Study NCT03191422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LSVT BIG
Description: LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
Study NCT03869983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnipaque™ (iohexol) Injection
Description: 755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
Study NCT03869983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CE-Iohexol
Description: 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
Study NCT03576612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Given IT
Study NCT03576612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Given PO days 1-14; 1-3 days post surgery
Study NCT03576612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
Study NCT03576612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
Study NCT03576612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
Study NCT03576612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: correlative studies
Study NCT02061774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 gram of intravenous Acetaminophen